COVID Vaccine Won't Trigger MS Relapse: Study
By Ernie Mundell HealthDay Reporter
WEDNESDAY, Aug. 21, 2024 -- Multiple sclerosis makes people vulnerable to more severe cases of COVID-19, but a new study finds that getting the COVID vaccine won't trigger a relapse of MS symptoms.
“People with MS have an increased risk of severe COVID infection due to their level of motor disability or exposure to treatments that suppress their immune systems,” explained study lead author Dr. Xavier Moisset, of Clermont Auvergne University in Clermont-Ferrand, France.
“Some previous studies have found relapses following vaccination, leading some people to not seek the recommended booster doses," he noted. "The good news is that our study found that there was no increased risk of relapse after COVID-19 vaccination for nearly all participants.”
The findings were published recently in the journal Neurology.
The research included 124,545 French people diagnosed with MS for an average of 14 years.
A majority (82%) had gotten at least one dose of a COVID vaccine, and of that group 95% went on to get a second dose while 59% got an extra booster dose.
Because any vaccine-linked relapse of MS typically occurs within 28 days of immunization, Moisset's team tracked outcomes for all participants within 45 days of getting a COVID shot. Vaccines were made by Pfizer, Moderna, AstraZeneca or Janssen.
There was no link between getting the COVID vaccine or booster and the odds for severe relapse, the team reported. They factored out other issues that might help spur relapse, such as the time of year or certain treatments.
Comparing folks who did experience relapse against those who did not, the researchers again found no connection to COVID vaccination. In fact, under this analysis vaccination appeared linked to a slightly lower risk for MS relapse.
“Our findings are reassuring that these vaccines can be used without any worry about the risk of relapse,” Moisset said in a journal news release. “The absence of such a risk is encouraging for people with MS that they may receive booster shots when needed, especially if booster shots are to be repeated in the future.”
There was one exception: People with highly active MS who were untreated before they got a COVID shot did seem to have a small increased risk for relapse after receiving their third (booster) dose of vaccine, the study found. Those patients "should first receive disease-modifying treatment before their booster vaccination," Moisset advised.
The study only looked at severe relapses that required corticosteroid treatment; it did not examine the risk of milder, "benign" relapse that does not need neurologist care.
Sources
- Neurology, news release, Aug. 14, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted August 2024
Further Support and Information on COVID-19
Read this next
No Link Found Between Migraines, Parkinson's Disease
FRIDAY, Aug. 23, 2024 -- Women who suffer frequent migraines don’t have any increased risk of developing Parkinson’s disease, finds a new study that refutes earlier...
Not Just Cancer: HPV May Hamper Men's Fertility
FRIDAY, Aug. 23, 2024 -- Human papillomavirus (HPV) has largely been seen as a health problem of women, given that it causes nearly all cases of cervical cancer. But men also...
FDA Approves Updated COVID Shots for Fall
THURSDAY, Aug. 22, 2024 -- Updated shots to shield against COVID-19 infection were approved by the U.S. Food and Drug Administration on Thursday. This year's approval for the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.